Article Contents ::
- 1 Details About Generic Salt :: Ceftazid
- 2 Main Medicine Class:: Antibiotic,cephalosporin
- 3 (seff-TAZE-ih-deem) Ceptaz, Fortaz, Tazicef, Tazidime Class: Antibiotic/cephalosporin
- 4 Drugs Class ::
- 5 Disclaimer ::
- 6 The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.
Details About Generic Salt :: Ceftazid
Main Medicine Class:: Antibiotic,cephalosporin
Ceptaz, Fortaz, Tazicef, Tazidime
Drugs Class ::
Action Inhibits mucopeptide synthesis in bacterial cell wall.
Indications for Drugs ::
Indications Treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis due to susceptible strains of specific microorganisms; concomitant antibiotic therapy.
Drug Dose ::
ADULTS: IV/IM 250 mg-2 g q 8–12 hr. CHILDREN 1 MO-12 YR: IV 30–50 mg/kg q 8 hr (maximum:6 g/day). NEONATES < 4 WK: IV 30 mg/kg q 12 hr.
Contraindications Hypersensitivity to cephalosporins.
Drug Precautions ::
Pregnancy: Category B. Lactation: Excreted in breast milk. Hypersensitivity: Reactions range from mild to life-threatening. Administer drug with caution to penicillin-sensitive patients due to possible cross-reactivity. Pseudomembranous colitis: Should be considered in patients in whom diarrhea develops. Renal impairment: Use drug with caution in patients with renal impairment. Dosage adjustment based on renal function may be required. Superinfection: May result in bacterial or fungal overgrowth of nonsusceptible microorganisms.
PATIENT CARE CONSIDERATIONS
Drug Side Effects ::
GI: Nausea; vomiting; diarrhea; anorexia; abdominal pain or cramps; flatulence; colitis, including pseudomembranous colitis. GU: Pyuria; renal dysfunction; dysuria; reversible interstitial nephritis; hematuria; toxic nephropathy. HEMA: Eosinophilia; neutropenia; lymphocytosis; leukocytosis; thrombocytopenia; thrombocytosis; decreased platelet function; anemia; aplastic anemia; hemorrhage. HEPA: Hepatic dysfunction; cholestatic jaundice; abnormal liver function test results. OTHER: Hypersensitivity, including Stevens-Johnson syndrome, erythema multiforme, toxic epidermal necrolysis; candidal overgrowth; serum sickness-like reactions (eg, skin rashes, polyarthritis, arthralgia, fever); phlebitis; thrombophlebitis and pain at injection site.
Drug Mode of Action ::
Action Inhibits mucopeptide synthesis in bacterial cell wall.
Drug Interactions ::
Aminoglycosides: Increased risk of nephrotoxicity. INCOMPATIBILITIES: Aminoglycosides: Do not add aminoglycosides to ceftazidime solutions because inactivation of both drugs may result; administer at separate sites if con current therapy is indicated. Sodium bicarbonate: Do not dilute ceftazidime with sodium bicarbonate.
Drug Assesment ::
- Obtain patient history, including drug history and any known allergies. Note renal impairment and allergy to cephalosporins or penicillins.
- Obtain specimens for culture and sensitivity before beginning therapy and periodically during treatment.
- Monitor renal function carefully during treatment.
- Monitor for signs of infection, especially fever, and for positive response to antibiotic therapy.
- Assess for signs and symptoms of anaphylaxis (shortness of breath, wheezing, laryngeal spasm). Have resuscitation equipment available.
- Assess for signs of superinfection, such as vaginitis or stomatitis.
- Assess for diarrhea with blood or pus, which may be symptom of pseudomembranous colitis. Symptoms may occur after antibiotic treatment.
- Monitor IV site for infiltration, infection, thrombophlebitis and bleeding.
Drug Storage/Management ::
- Administer by parenteral route (IV or IM) only.
- Follow manufacturer’s instructions for reconstitution and dilution.
- Reconstituted solution should be light yellow to amber; darkened solution or powder does not indicate altered potency. Do not administer if solution is cloudy or precipitate is present.
- When giving by IM route, add 3 ml diluent to 1-g vial to yield 280 mg/ml. Inject deeply into large muscle (eg, upper outer quadrant of gluteus muscle or lateral thigh); massage well.
- When giving by IV route, add 10 ml Sterile Water for Injection to 1-g vial to yield 280 mg/ml. Administer slowly over 3–5 min. Change IV sites q 48–72 hr.
- For intermittent infusions, reconstituted solution can be further diluted with 50–100 ml of D5W or 0.9% sodium chloride and infused over 30 min.
- Store sterile powder at room temperature and protect from light.
- When reconstituted with Sterile Water for Injection, solution is stable for 7 days if refrigerated and for 18–24 hr when stored at room temperature. If frozen immediately after reconstitution, solution is stable for 3 mo. Completely thaw frozen preparation at room temperature before use. After thawing, solution may be stored for 18–24 hr at room temperature or 4 days in refrigerator. Do not refreeze.
Drug Notes ::
- Remind patient to check body temperature daily. If fever persists for more than a few days or if high fever (> 102°F) or shaking chills are noted, physician should be notified immediately.
- Advise patient to maintain normal fluid intake while using this medication.
- Remind diabetic patient to use enzyme-based tests (eg, Clinistix, Testape) for monitoring urine glucose because drug may give false results with other tests.
- Advise patient to report these symptoms to physician: nausea, vomiting, diarrhea, skin rash, hives, sore throat, bruising, bleeding, muscle or joint pain.
- Instruct patient to report signs of superinfection: black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.
- Warn patient that diarrhea that contains blood or pus may be a sign of serious disorders. Tell patient to seek medical care and not to treat at home.
- Instruct patient to seek emergency care immediately if wheezing or difficulty breathing occurs.
- Advise patient not to drink alcoholic beverages or to take alcohol-containing medications while taking this medication and for several days after discontinuing it.